GENETIC ANALYSIS NK -60 (F:8V8) — Market Cap & Net Worth
Market Cap & Net Worth: GENETIC ANALYSIS NK -60 (8V8)
GENETIC ANALYSIS NK -60 (F:8V8) has a market capitalization of $2.36 Million (€2.02 Million) as of September 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #29893 globally and #2586 in its home market, demonstrating a -7.02% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GENETIC ANALYSIS NK -60's stock price €0.03 by its total outstanding shares 69087041 (69.09 Million). Also see GENETIC ANALYSIS NK -60 (8V8) total assets for a full breakdown of the balance sheet.
GENETIC ANALYSIS NK -60 Market Cap History: 2021 to 2026
GENETIC ANALYSIS NK -60's market capitalization history from 2021 to 2026. Data shows change from $48.70 Million to $2.57 Million (-49.19% CAGR). Also see how efficiently does GENETIC ANALYSIS NK -60 generate cash for how efficiently the company converts equity into cash flow.
GENETIC ANALYSIS NK -60 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GENETIC ANALYSIS NK -60's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for GENETIC ANALYSIS NK -60 for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.21x
GENETIC ANALYSIS NK -60's market cap is 0.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $48.70 Million | $6.80 Million | -$29.01 Million | 7.16x | N/A |
| 2022 | $13.38 Million | $11.16 Million | -$28.27 Million | 1.20x | N/A |
| 2023 | $4.35 Million | $14.15 Million | -$23.82 Million | 0.31x | N/A |
| 2024 | $1.83 Million | $15.89 Million | -$14.77 Million | 0.11x | N/A |
| 2025 | $3.43 Million | $16.71 Million | -$11.41 Million | 0.21x | N/A |
Competitor Companies of 8V8 by Market Capitalization
Companies near GENETIC ANALYSIS NK -60 in the global market cap rankings as of September 19, 2026. Review 8V8 tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to GENETIC ANALYSIS NK -60 by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #89 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #161 globally with a market cap of $149.61 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #475 globally with a market cap of $57.91 Billion USD ( CN¥395.72 Billion CNY).
- Natera Inc (NASDAQ:NTRA): Ranked #577 globally with a market cap of $47.01 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #89 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $651.45 |
| #161 | Danaher Corporation | NYSE:DHR | $149.61 Billion | $211.81 |
| #475 | WuXi AppTec Co Ltd | SHG:603259 | $57.91 Billion | CN¥160.00 |
| #577 | Natera Inc | NASDAQ:NTRA | $47.01 Billion | $369.39 |
GENETIC ANALYSIS NK -60 Historical Marketcap From 2021 to 2026
Between 2021 and today, GENETIC ANALYSIS NK -60's market cap moved from $48.70 Million to $ 2.57 Million, with a yearly change of -49.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.57 Million | -25.18% |
| 2025 | €3.43 Million | +88.05% |
| 2024 | €1.83 Million | -57.99% |
| 2023 | €4.35 Million | -67.51% |
| 2022 | €13.38 Million | -72.54% |
| 2021 | €48.70 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of GENETIC ANALYSIS NK -60 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.36 Million USD |
| MoneyControl | $2.36 Million USD |
| MarketWatch | $2.36 Million USD |
| marketcap.company | $2.36 Million USD |
| Reuters | $2.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GENETIC ANALYSIS NK -60
Genetic Analysis AS, a science-based diagnostic company, engages in the research, development, manufacturing, and sale of diagnostic test solutions for human microbiome in the United States, Europe, and internationally. The company offers GA-map MHI Gut Health Test, a microbiome-based diagnostic test for antibiotic-induced microbiome imbalances; GA-map Dysbiosis Test, a diagnostic microbiome test… Read more